The first major reduction in AIDS-related mortality came with the introduction of protease inhibitors (PIs) as part of combination therapy during the mid- and late 1990s.1,2 Despite their significant role in slowing HIV progression, PIs—most notably, the first-generation compounds—have been associated with significant acute and chronic toxicities, including gastrointestinal disturbances; lipid, glucose, and